

Message

From: Mead, Ralph N. [meadr@uncw.edu]
Sent: 2/23/2018 5:53:40 PM
To: Strynar, Mark [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5a9910d5b38e471497bd875fd329a20a-Strynar, Mark]; Mark Strynar
CC: McCord, James [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=McCord, James]
Subject: Re: PO# P0112499
Attachments: image001.jpg; image002.png

Hi Mark,

My address is:

ATTN: Ralph Mead
Department of Chemistry and Biochemistry
UNCW
601 South College Road
Wilmington, NC 28409

Thanks!
Ralph

-- Ralph N. Mead Ph.D.
Professor
Dobo 242b
Department of Chemistry and Biochemistry
UNCW
Office: 910-962-2447

From: "Strynar, Mark" <Strynar.Mark@epa.gov>
Date: Thursday, February 22, 2018 at 1:27 PM
To: Ralph Mead <meadr@uncw.edu>, Mark Strynar <Strynar.Mark@epa.gov>
Cc: "McCord, James" <mccord.james@epa.gov>
Subject: RE: PO# P0112499

Ex. 6 Personal Privacy (PP)

Ralph,

Our address is:

Attn: Mark Strynar
US EPA
108 TW Alexander Drive
Chemical Services Loading Dock E
Durham, NC 27711.

I will weigh out ~ 10 mg of Nafion BP1 and BP2. Give me an address to send it to you.

Mark

From: Mead, Ralph N. [<mailto:meadr@uncw.edu>]
Sent: Thursday, February 22, 2018 11:16 AM
To: Strynar, Mark <Strynar.Mark@epa.gov>; Mark Strynar <markstrynar@gmail.com>
Subject: FW: PO# P0112499
Importance: High

PFMOAA source

-- Ralph N. Mead Ph.D.
Professor
Dobo 242b
Department of Chemistry and Biochemistry
UNCW
Office: 910-962-2447

From: Sales <sales@zerenex-molecular.com>
Date: Wednesday, February 14, 2018 at 10:11 AM
To: Ralph Mead <meadr@uncw.edu>, "Fisher, Kimberly K." <fisherk@uncw.edu>
Subject: RE: PO# P0112499

Hello Ralph

Further to the order the chemist has now successfully synthesised the ordered compound and the material is being prepared for shipment today/tomorrow. Apologies for the delay.

Kind Regards

Kathrin

Sales

zerenex™
m o l e c u l a r Tel: +44 (0) 845 2993935
Fax: +44 (0) 1204 441363
www.zerenex-molecular.com

Notice: This e-mail message, together with any attachments, contains information belonging to Zerenex Molecular Ltd that may be confidential, proprietary, copyrighted, privileged and/or protected work product, and is meant solely for the intended recipient. If you are not the intended recipient, and have received this message in error, please contact the sender immediately, permanently delete the original and any copies of this email and any attachments thereto.

From: Mead, Ralph N. [<mailto:meadr@uncw.edu>]
Sent: 17 January 2018 15:38
To: Fisher, Kimberly K.; sales@zerenex-molecular.com
Subject: Re: PO# P0112499

Dear James,

Thank you for your efforts. After considerable discussion with my colleagues the benzyl analogue will not suite our needs. Therefore we cannot accept it.

Thank you very much.

Ralph

-- Ralph N. Mead Ph.D.
Professor
Dobo 242b
Department of Chemistry and Biochemistry
UNCW
Office: 910-962-2447

From: "Fisher, Kimberly K." <fisherk@uncw.edu>
Date: Tuesday, January 9, 2018 at 11:31 AM
To: Ralph Mead <meadr@uncw.edu>
Subject: FW: PO# P0112499

Ralph,
Please respond to sales@zerenex-molecular.com for the below comment from Zerenex


Thanks,
Kim

From: Sales [<mailto:sales@zerenex-molecular.com>]
Sent: Monday, January 08, 2018 6:44 AM
To: Fisher, Kimberly K. <fisherk@uncw.edu>
Subject: PO# P0112499
Importance: High

Hello Kimberly

Further to your order please kindly see chemist comments below and advise?

Please find the synthetic route that was planned for the target compound's obtaining below



a: R= Et
b: R= Bn

Please be advised that in the Route "a" (when ethyl derivative was used) we registered compound 2a forming according to the ^{19}F NMR spectra, however it's isolation from the mixture was unsuccessful due to its high volatility.

As a result we performed alkaline "In situ" hydrolysis which resulted in the decomposition of the obtained compound unfortunately forming an in-separable mixture.

Via Route "b" (when corresponding benzyl derivative was used) we have successfully obtained compound 2b (please refer to attachment for the spectral data). However as of yet we not yet identified the conditions to access compound 3

Please kindly confirm that you will accept the equivalent amount of analogue benzyl derivative (2b) as a substitution for the acid as we have spent considerable time/effort and resources in getting to this stage.

Thank you in advance and I look forward to hearing from you

Kind Regards

James

Sales

zerenex[™]
m o l e c u l a r Tel: +44 (0) 845 2903935
Fax: +44 (0) 1204 441363
www.zerenex-molecular.com

Notice: This e-mail message, together with any attachments, contains information belonging to Zerenex Molecular Ltd that may be confidential, proprietary, copyrighted, privileged and/or protected work product, and is meant solely for the intended recipient. If you are not the intended recipient, and have received this message in error, please contact the sender immediately, permanently delete the original and any copies of this email and any attachments thereto.